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ABSTRACT  
Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exac-
erbations in many patients. There have been no previous international guidelines.  
The European Respiratory Society Guidelines for the Management of Adult Bronchiectasis describe 
the appropriate investigation and treatment strategies determined by a systematic review of the lit-
erature.  
A multidisciplinary group representing respiratory medicine, microbiology, physiotherapy, thoracic 
surgery, primary care, methodology and patients considered the most relevant clinical questions (for 
both clinicians and patients) related to management of bronchiectasis. Nine key clinical questions 
were generated and a systematic review was conducted to identify published systematic reviews, 
randomized clinical trials and observational studies that answered these questions. We used the 
GRADE approach to define the quality of the evidence and the level of recommendations. The result-
ing guideline addresses the investigation of underlying causes of bronchiectasis, treatment of exac-
erbations, pathogen eradication, long term antibiotic treatment, anti-inflammatories, mucoactive 
drugs, bronchodilators, surgical treatment and respiratory physiotherapy.   
These recommendations can be used to benchmark quality of care for people with bronchiectasis across 
Europe and to improve outcomes. 
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Scope and objectives 
This guideline provides evidence-based recommendations for the management of adult patients with 
bronchiectasis. It only applies to patients with clinically significant bronchiectasis, defined by the pres-
ence of both permanent bronchial dilatation on CT scanning and the clinical syndrome of cough, sputum 
production and/or recurrent respiratory infections. Radiological bronchiectasis may be evident in 
healthy asymptomatic individuals, particularly in the elderly[1] or may occur, for example, due to trac-
tion in interstitial lung disease. Such radiological bronchiectasis without clinical symptoms are not ad-
dressed in this guideline.  The following conditions are also excluded: cystic fibrosis (CF) bronchiectasis, 
which has a distinct pathophysiology and treatment pathway, children with bronchiectasis, treatment 
of primary immunodeficiencies and non-tuberculous mycobacteria, where disease specific therapy is 
indicated. The majority of these clinical issues are addressed in other guidelines.  
This guideline document does not address clinical and radiological diagnosis of bronchiectasis but ra-
ther focuses on key questions in management. Areas such as smoking cessation, nutrition, influenza and 
pneumococcal vaccination among other aspects of general management are not specifically addressed 
in this document. Readers are referred to relevance guidelines and national policies. A guideline docu-
ment cannot address the full complexity of a disease such as bronchiectasis, hence all recommendations 
should be interpreted taking into account the clinical circumstances and patients’ perceptions, values 
and preferences.   
 
Table 1 provides a framework to understand the recommendations made in this document[2, 3]. 
 
Target 
group 
Strong recommendations* 
Conditional (weak) recommenda-
tions 
Patients All or almost all informed peo-
ple would choose the recom-
mended choice for or against 
an intervention.  
Most informed people would choose the 
recommended course of action, 
but a substantial number would not.  
Clinicians Most patients should receive 
the recommended course of 
action 
Recognize that different choices will be 
appropriate for different patients. Clini-
cians and other health care providers 
need to devote more time to the process 
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of shared decision making by which 
they ensure that the informed choice re-
flects individual values and preferences; 
decision aids and shared decision mak-
ing are particularly useful 
Policy 
makers 
The recommendation can be 
adopted as a policy in most 
situations 
Policy making will require substantial 
debate and involvement of many stake-
holders 
GRADE, Grades of Recommendation, Assessment, Development and Evaluation. 
*Strong recommendations based on high quality evidence will apply to most patients for whom these recom-
mendations are made, but they may not apply to all patients in all conditions; no recommendation can take into 
account all of the unique features of individual patients and clinical circumstances. 
 
The target audience for this guideline are all stakeholders involved bronchiectasis care. This includes 
specialists in respiratory medicine, infectious diseases, clinical microbiology, general internists, spe-
cialists in thoracic surgery, primary care physicians, pharmacists, respiratory physiotherapists, special-
ist nurses, regulatory authorities, pharmaceutical companies and policy makers. The guideline is also 
to inform people with BE to help them in discussion with their care teams to enable them to access 
appropriate care. 
 
Introduction 
Bronchiectasis is a chronic respiratory disease characterised by a clinical syndrome of cough, sputum 
production and bronchial infection, and radiologically by abnormal and permanent dilatation of the 
bronchi. The objectives of treatment in bronchiectasis are to prevent exacerbations, reduce symptoms, 
improve quality of life and stop disease progression. Cough and sputum production, along with breath-
lessness are the most frequent symptoms but rhino-sinusitis, fatigue, haemoptysis and thoracic pain 
are also common[4]. Quality of life impairment in bronchiectasis is equivalent in terms of scores on the 
St. Georges respiratory questionnaire (SGRQ) to severe COPD, idiopathic pulmonary fibrosis and other 
disabling respiratory diseases[5, 6]. 
Exacerbations of bronchiectasis are key targets for therapy as they are major determinants of 
healthcare costs. They are associated with increased airways and systemic inflammation[7]and pro-
gressive lung damage[8, 9]. In addition, more severe and more frequent exacerbations are associated 
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with worse quality of life, daily symptoms[10], lung function decline[11], and mortality [9]. Conse-
quently, the majority of therapeutic interventions are aimed at reducing exacerbations. Despite current 
treatment approaches, European registry data shows that approximately 50% of European bronchiec-
tasis patients have 2 or more exacerbations per year and one third require at least 1 hospitalization per 
year[12]. 
Our understanding of what causes symptoms and exacerbations is based on the vicious cycle concept, 
with key components of the disease being chronic bronchial infection, inflammation, impaired mucocil-
iary clearance and structural lung damage. Treatment is primarily based on the principles of preventing 
or suppressing acute and chronic bronchial infection, improving mucociliary clearance and reducing 
the impact of structural lung disease (Figure 1). 
Chronic airways infection, most frequently with Haemophilus influenzae and Pseudomonas aeruginosa 
and less frequently with Moraxella catarrhalis, Staphylococcus aureus and Enterobacteriaceae, stimulate 
and sustain lung inflammation. Persistent isolation of these organisms in sputum or bronchoalveolar 
lavage is associated with an increased frequency of exacerbations, worse quality of life and increased 
mortality[13, 14]. This is particularly the case with P. aeruginosa infection. A systematic review of ob-
servational studies identified that P. aeruginosa infection is associated with a 3-fold increase in mortal-
ity risk, an almost 7-fold increase in risk of hospital admission and an average of 1 additional exacerba-
tion per patient per year[15]. 
 
Inflammation in bronchiectasis is primarily neutrophilic and closely linked to persistent bacterial in-
fection. Excessive neutrophilic inflammation is linked to an increased frequency of exacerbations and 
rapid lung function decline through degradation of airway elastin among other mechanisms [16-19]. 
The available data also support a role for cell-mediated immunity, specifically T-cells in the pathophys-
iology of bronchiectasis but the role of other inflammatory cells is less clear[17]. 
 
Mucociliary clearance is impaired by the impact of structural bronchiectasis, airway dehydration, ex-
cess mucus volume and viscosity. More than 70% of bronchiectasis patients expectorate sputum daily 
with highly variable sputum volumes. Treatment aims to prevent mucus stasis and the associated mu-
cus plugging, airflow obstruction and progressive lung damage[20]. 
 
Structural lung disease includes bronchial dilatation, bronchial wall thickening, and mucus plugging as 
well as small airways disease and emphysema.  More than 50% of patients have airflow obstruction, 
but restrictive, mixed ventilatory pattern and preserved lung function are also frequently observed. 
Breathlessness is due to the impact of airflow obstruction, impaired gas transfer, exercise decondition-
ing and the impact of co-morbidities[21-24]. Breathlessness is one of the strongest predictors of mor-
tality[9, 14]. Therapies may aim to treat airflow obstruction (e.g. bronchodilators), to improve exercise 
 {PAGE  } 
capacity (pulmonary rehabilitation), or to remove poorly functioning or diseased lung (e.g. surgery). 
 
 
Bronchiectasis has long been a neglected disease. The prevalence of bronchiectasis has been estimated 
at 53 to 566 cases per 100,000 inhabitants. Prevalence increases with age and female gender [25-29]. 
Quint et al. described that age-adjusted mortality rate for bronchiectasis was 1437.7 per 100,000.[28] 
Several longitudinal studies have described up to a 30% mortality at 1-year follow-up after suffering an 
exacerbation [30,31], particularly in the presence of COPD[32]. 
The economic burden of this disease has been estimated to be similar to COPD; this increases with dis-
ease severity, hospitalizations, ICU, and use of inhaled antibiotics [25, 26, 30, 33-35]. No therapies are 
currently specifically licensed by regulatory authorities in Europe or the United States for the treatment 
of bronchiectasis. Historically, treatment has been extrapolated from the management of CF bronchiec-
tasis, but randomized clinical trials and clinical experience has often demonstrated that treatment re-
sponses are different and that specific guidance for bronchiectasis not due to CF is necessary [36, 37]. 
National guidelines are available in Europe: the Spanish guidelines (SEPAR) were published in 2008 
[38] and the British Thoracic Society guidelines were published in 2010 [39]. Aspects of management 
of acute exacerbations in bronchiectasis were addressed in the ERS/ESCMID lower respiratory tract 
infections guidelines published in 2011[40]. However, to date, there are no international guidelines for 
the management of adult bronchiectasis published and no national guidelines published in Europe in 
the past 5 years. 
 
METHODS 
This guideline was developed by a European Respiratory Society Bronchiectasis Task Force chaired by 
Dr Eva Polverino (Spain) and Dr James D Chalmers (UK). The task force included specialists in respira-
tory medicine with recognized expertise in the management of patients with lung infections, as well as 
a microbiologist, an immunologist, a physiotherapist, a general practitioner, a thoracic surgeon, 3 pa-
tient representatives from the EMBARC/European Lung Foundation (ELF) bronchiectasis patient advi-
sory group and two ERS methodologists.  
The guideline panel held four face-to-face meetings, beginning in January 2015. The most relevant clin-
ical questions on the management of bronchiectasis in adults (for both clinicians and patients) were 
debated. A total of 9 clinical questions were formulated using the PICO format (PICO: Patients, Inter-
vention, Comparison, Outcomes) and systematic reviews were conducted to answer these specific ques-
tions, until September 2016 when the final guideline recommendations were discussed and agreed. 
Regular teleconferences and discussions via e-mail around individual topics were held. The patient rep-
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resentatives were actively involved in all discussions as full members of the guideline committee, pro-
vided input into the final recommendations and will be involved in developing a lay version of the guide-
line. 
 
Disclosure of potential conflicts of interest 
Committee members disclosed all potential conflicts of interest according to ERS policy. Conflicted 
members were asked to abstain from discussions and voting on recommendations in which they were 
considered to have potential conflicts. Compliance with the conflict of interest policy was monitored by 
the chairs. The methodologists were non-voting members of the panel. 
 
Systematic review 
An experienced external librarian designed and ran a search strategy using MeSH terms and keywords 
for each clinical question, in collaboration with the methodologists. More details of the search strategy 
are shown in the online supplemental material. The search retrieved 3,038 records; after removal of 
duplicates and exclusion of citations that did not meet the established inclusion criteria, a total of 48 
references were included in the evidence summaries (Figure 2; online material). 
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Assessment of the level of evidence and degree of recommendations 
The panel selected outcomes of interest for each clinical question a priori, based on their relative im-
portance to adult patients with bronchiectasis and to clinical decision making (online material).  
We followed the GRADE approach to assess the confidence in the evidence (quality) and the degree of 
recommendations[41]. Recommendations are graded as strong or conditional after considering the 
quality of the evidence, the balance of desirable and undesirable consequences of compared manage-
ment options, the assumptions about the relative importance of outcomes, the implications for resource 
use, and the acceptability and feasibility of implementation[42]. 
Evidence summaries of findings (SoF tables) and Evidence to Decisions (EtD) frameworks were gener-
ated for each clinical question [43] (online material). Based on these formats, the panel formulated the 
clinical recommendations and decided on their strength by consensus and, if required, by voting. Fol-
lowing the GRADE approach, strong recommendations are worded as “we recommend”, while condi-
tional recommendations are worded as “we suggest”.  
 
 
Table 2  SUMMARY OF PICO QUESTIONS AND RECOMMENDATIONS  
 
 
QUESTION TITLE RECOMMENDATIONS 
Question 1 Is the application of current 
SEPAR/BTS recommendations 
about aetiological testing panel 
of bronchiectasis beneficial for 
their clinical management in 
comparison with no standard-
ized aetiological testing? 
We suggest the minimum bundle of 
aetiological tests in adults with a 
new diagnosis of bronchiectasis 
(conditional recommendation, very 
low quality of evidence) is: 
1. Differential blood count  
2. Serum immunoglobulins 
(total IgG, IgA, IgM) 
3. Testing for allergic bron-
chopulmonary aspergillosis 
(ABPA) 
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It is expected that sputum culture 
is undertaken for monitoring pur-
poses of bacterial infection. Myco-
bacterial culture may be helpful in 
selected cases where non-tubercu-
lous mycobacteria (NTM) are sus-
pected as an aetiological cause of 
bronchiectasis. Additional tests 
may be appropriate in response to 
specific clinical features, or in pa-
tients with severe or rapidly pro-
gressive disease.  
Question 2 
 
Are courses of 14-21 days of 
systemic antibiotic therapy 
compared to shorter courses 
(<14 days) beneficial for treat-
ing adult BE patients with an 
acute exacerbation? 
We suggest acute exacerbations of 
bronchiectasis should be treated 
with 14 days of antibiotics (condi-
tional recommendation, very low 
quality of evidence). 
It is possible that shorter or longer 
courses of antibiotics may be ap-
propriate in some cases, depending 
on specific clinical conditions (such 
as exacerbation severity, patient’ 
response to treatment, or microbi-
ology) 
Question 3  Is an eradication treatment 
beneficial for treating BE pa-
tients with a new isolate of a 
potentially pathogenic micro-
organism in comparison to no 
eradication treatment? 
- We suggest that adults with bron-
chiectasis with a new isolation of 
P. aeruginosa should be offered 
eradication antibiotic treatment 
(conditional recommendation, 
very low quality of evidence). 
- We suggest not offering eradica-
tion antibiotic treatment to 
adults with bronchiectasis fol-
lowing new isolation of patho-
gens other than P. aeruginosa 
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(conditional recommendation, 
very low quality of evidence)  
 
Question 4 
 
Is long-term (≥ 3 months) anti-
inflammatory treatment com-
pared to no treatment benefi-
cial for treating adult bronchi-
ectasis patients? 
- We suggest not offering treat-
ment with inhaled corticoster-
oids to adults with bronchiectasis 
(conditional recommendation, 
low quality of evidence).  
- We recommend not offering 
statins for the treatment of bron-
chiectasis (strong recommenda-
tion, low quality of evidence). 
- We suggest that the diagnosis of 
bronchiectasis should not affect 
the use of inhaled corticosteroids 
in patients with comorbid asthma 
or COPD (Best practice advice, in-
direct evidence). 
Question 5  
 
Is long-term antibiotic treat-
ment (≥3 months) compared 
to no treatment beneficial for 
treating adult bronchiectasis 
patients? 
We suggest offering long-term an-
tibiotic treatment for adults with 
bronchiectasis who have three or 
more exacerbations per year (con-
ditional recommendation, moderate 
quality evidence). All subsequent 
recommendations refer to patients 
with three or more exacerbations 
per year. 
 
- We suggest long-term treatment 
with an inhaled antibiotic for 
adults with bronchiectasis and 
chronic P. aeruginosa infection 
(conditional recommendation, 
moderate quality evidence). 
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- We suggest macrolides (azithro-
mycin, erythromycin) for adults 
with bronchiectasis and chronic 
P. aeruginosa infection in whom 
an inhaled antibiotic is contrain-
dicated, not tolerated or not fea-
sible (conditional recommenda-
tion, low quality evidence). 
 
- We suggest macrolides (azithro-
mycin, erythromycin) in addition 
to or in place of an inhaled antibi-
otic, for adults with bronchiecta-
sis and chronic P. aeruginosa in-
fection who have a high exacerba-
tion frequency despite taking an 
inhaled antibiotic (conditional 
recommendation, low quality evi-
dence).  
 
- We suggest long-term macrolides 
(azithromycin, erythromycin) for 
adults with bronchiectasis not in-
fected with P.  aeruginosa (condi-
tional recommendation, moderate 
quality evidence).  
 
- We suggest long-term treatment 
with an oral antibiotic (choice 
based on antibiotic susceptibility 
and patient tolerance) for adults 
with bronchiectasis not infected 
with P. aeruginosa in whom mac-
rolides are contraindicated, not 
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tolerated or ineffective (condi-
tional recommendation, low qual-
ity evidence). 
 
- We suggest long-term treatment 
with an inhaled antibiotic for 
adults with bronchiectasis not in-
fected with P. aeruginosa in 
whom oral antibiotic prophylaxis 
is contraindicated, not tolerated 
or ineffective (conditional recom-
mendation, low quality of evi-
dence). 
 
- Long-term antibiotic therapy 
should be considered only after 
optimisation of general aspects of 
bronchiectasis management 
(airway clearance and treating 
modifiable underlying causes). 
 
Question 6  
 
Is long-term mucoactive treat-
ment (≥3 months) compared 
to no treatment beneficial for 
treating adult bronchiectasis 
patients? 
We suggest offering long-term mu-
coactive treatment (≥ 3 months) in 
adult patients with bronchiectasis 
who have difficulty in expectorat-
ing sputum and poor quality of life 
and where standard airway clear-
ance techniques have failed to con-
trol symptoms (weak recommenda-
tion, low quality evidence).  
We recommend not offering re-
combinant human DNase to adult 
patients with bronchiectasis 
(strong recommendation, moderate 
quality evidence)  
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Question 7 
 
Is long-term bronchodilator 
treatment (≥3 months) com-
pared to no treatment benefi-
cial for adult bronchiectasis 
patients? 
We suggest not routinely offering 
long-acting bronchodilators for 
adult patients with bronchiectasis 
(conditional recommendation, very 
low quality of evidence)  
 
We suggest offering long acting 
bronchodilators for patients with 
significant breathlessness on an in-
dividual basis (weak recommenda-
tion, very low quality of evidence). 
 
We suggest using bronchodilators 
before physiotherapy, including in-
haled mucoactive drugs, as well as 
before inhaled antibiotics, in order 
to increase tolerability and opti-
mize pulmonary deposition in dis-
eased areas of the lungs (good 
practice point, indirect evidence). 
We suggest that the diagnosis of 
bronchiectasis should not affect 
the use of long acting bronchodila-
tors in patients with comorbid 
asthma or COPD [44][45] (good 
practice point, indirect evidence). 
Question 8 
 
Are surgical interventions 
more beneficial compared to 
standard (non-surgical) treat-
ment for adult bronchiectasis 
patients?  
 
We suggest not offering surgical 
treatments for adult patients with 
bronchiectasis with the exception 
of patients with localised disease 
and a high exacerbation frequency 
despite optimisation of all other as-
pects of their bronchiectasis man-
agement (weak recommendation, 
very low quality of evidence).  
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Question 9 
 
Is regular physiotherapy (air-
way clearance and/or pulmo-
nary rehabilitation) more ben-
eficial than control (no physio-
therapy) in adult bronchiecta-
sis patients? 
- We suggest that patients with 
chronic productive cough or diffi-
culty to expectorate sputum 
should be taught an airways 
clearance technique (ACT) by a 
trained respiratory physiothera-
pist to perform once or twice 
daily (weak recommendation, low 
quality of evidence).  
- We recommend that adult pa-
tients with bronchiectasis and 
impaired exercise capacity 
should participate in a pulmo-
nary rehabilitiation program and 
take regular exercise. All inter-
ventions should be tailored to the 
patient’s symptoms, physical ca-
pability and disease characteris-
tics (strong recommendation, 
high quality of evidence).  
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Question 1: Is the application of current SEPAR/BTS recommendations about aetiological testing 
panel of bronchiectasis beneficial for their clinical management in comparison with no stand-
ardized aetiological testing? 
Recommendations 
We suggest the minimum bundle of aetiological tests in adults with a new diagnosis of bronchiectasis 
(conditional recommendation, very low quality of evidence) is: 
 Differential blood count  
 Serum immunoglobulins (total IgG, IgA, IgM) 
 Testing for allergic bronchopulmonary aspergillosis (ABPA) 
 
It is expected that sputum culture is undertaken for monitoring purposes of bacterial infection. Myco-
bacterial culture may be helpful in selected cases where non-tuberculous mycobacteria (NTM) are 
suspected as an aetiological cause of bronchiectasis. Additional tests may be appropriate in response 
to specific clinical features, or in patients with severe or rapidly progressive disease. 
 
Summary of the evidence 
The SEPAR and BTS guidelines have previously recommended a routine “bundle” of tests at diagnosis 
to identify possible underlying causes of bronchiectasis[38][39]. Our systematic review identified no 
publications which directly addressed whether routine aetiological investigation protocols provide 
benefit compared to clinically driven investigations or no testing. Four observational studies were iden-
tified which describe the percentage of adult patients (7%-37%) whose management changed following 
investigation of aetiology while no other relevant outcomes were reported[46-49]. 
 
Justification of the recommendation 
Measurement of circulating white cell count and differential is suggested in all patients.  The presence 
of lymphopaenia or neutropaenia may suggest primary or secondary immune deficiency, while lym-
phocytosis may suggest secondary immune deficiency as a consequence of haematological malignancy.  
Serum IgA, IgM, IgG are generally tested together, and we have considered them jointly.  Low IgG, with 
or without low IgM or low IgA may indicates a defective antibody production that is an important mod-
ifiable cause of bronchiectasis, and 2-8% of patients with bronchiectasis have common variable im-
mune deficiency[46-48]. Importantly, in these cases immunoglobulin replacement treatment can result 
in significant improvement in short and long-term outcomes.  The cost of serum immunoglobulin test-
ing is low and testing is readily available.   
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The geographic distribution of ABPA is thought to be variable, but establishing diagnosis alters man-
agement[49]. Hence the panel advises routine screening of all patients for ABPA at diagnosis. The gen-
erally recommended screening tests for ABPA are total serum IgE, specific IgG to Aspergillus, and spe-
cific IgE to Aspergillus or, as an alternative, skin prick tests to Aspergillus[50, 51]. 
A range of other tests may be appropriate in specific circumstances. In patients with radiological fea-
tures of NTM or clinical features such as weight loss, haemoptysis, rapid deterioration or symptoms 
non-responsive to standard therapy, three sequential daily sputum cultures for mycobacterial cultures 
or a single bronchoalveolar lavage (BAL) should be considered[52]. Some authorities recommend 
measuring antibody responses to S. pneumoniae 23 valent polysaccharide vaccine (PPV23) in order to 
identify individuals with specific polysaccharide antibody deficiency[38][39].  Failure to make an anti-
body response to PPV23 (4-fold increase in titre at 4-6 weeks) may suggest a defect in carbohydrate 
antigen responses. However, due to the large variability in individual antibody response to PPV23 and 
in testing protocols, this evaluation should not be performed without specialist support. Testing for CF 
with measurement of sweat chloride, other biomarkers of Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR)-mediated chloride ion transport and CFTR gene mutation analysis should be consid-
ered in young adults or with specific clinical features of CF such as upper lobe predominance of bron-
chiectasis on chest CT, the presence of nasal polyposis and/or chronic rhinosinusitis, recurrent pancre-
atitis, male primary infertility and/or malabsorption.  Testing for primary ciliary dyskinesia with nasal 
nitric oxide, high-speed video analysis, transmission electron microscopy, immunofluorescence and/or 
genetic testing should be considered for patients with several of the following features: persistent wet 
cough since childhood, situs anomalies, congenital cardiac defects, nasal polyposis and/or chronic rhi-
nosinusitis, chronic middle ear disease with or without hearing loss, a history of neonatal respiratory 
distress or neonatal intensive care admittance in term infants. Refer to the ERS guidelines for the diag-
nosis of PCD for more information[53]. The presence of basal emphysema or early onset airflow ob-
struction could suggest the need to exclude alpha1-antitrypsin deficiency. There are a wide range of 
other causes of bronchiectasis many of which can be identified by history, physical examination and CT 
scanning. We do not recommend routine testing of autoantibodies to screen for connective tissue dis-
ease, but evidence of connective tissue disease should be sought by history and physical examination. 
 
The suggested bundle is justified by the fact that, despite the lack of strong evidence, selected tests can 
considerably alter the clinical management of bronchiectasis by indicating specific therapeutic inter-
ventions such as immunoglobulin replacement, corticosteroids, or antifungal treatment.  These inter-
ventions imply significant potential benefits for some individuals, and minimal undesirable effects from 
testing for others. The patient advisory group reported that patients placed a high value on identifying 
the underlying cause of bronchiectasis.  
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Implementation considerations 
The standard tests recommended in this bundle should be available in the majority of healthcare sys-
tems and should not present major implementation issues.  
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Question 2: Are courses of 14-21 days of systemic antibiotic therapy compared to shorter courses 
(<14 days) beneficial for treating adult bronchiectasis patients with an acute exacerbation? 
 
Recommendation 
We suggest acute exacerbations of bronchiectasis should be treated with 14 days of antibiotics (condi-
tional recommendation, very low quality of evidence). 
 
Summary of the evidence 
Bronchiectasis patients are typically given prolonged courses of antibiotics of 14 days’ duration for in-
fective exacerbations.  This recommendation is given in previous guidelines for bronchiectasis [38,39]. 
It is based on expert consensus and studies that documented good clinical outcomes with such treat-
ment regimens.  However, the evidence base for this duration is poor. 
 
The published literature was assessed as to whether shorter (<14 days) courses of antibiotics would be 
as clinically effective or be associated with any benefit or harm compared to 14-21 days of therapy.  
There was no direct evidence of benefit favouring either 14-21 days or shorter courses of antibiotic 
therapy.  The only data comes from an indirect comparison of response at day 7 vs. day 14 in 53 patients, 
all receiving ciprofloxacin (with or without inhaled tobramycin) for 14 days. After pooling both study 
arms, bacterial load (MD: +0.23 cfu/ml higher; 95%CI: -1.55 to +2.01) and FEV1 (MD: +0.01 Litres; 
95%CI: -0.51 to +0.53) were similar at 7 and 14 days with wide confidence intervals including both 
benefit and harm. No data was available for clinical outcome such as subsequent quality of life and ex-
acerbations [54][ online material] 
 
Data from other studies. Some authors have shown a favourable impact of 14 days of antibiotics for 
treatment of a bronchiectasis exacerbation. One study of 32 exacerbations treated with 14 days of in-
travenous antibiotics demonstrated significant improvement in 24-hour sputum volume, bacterial 
clearance, C-reactive protein, incremental walk test and SGRQ but no improvement in spirometry[55]. 
A further study of 34 patients treated with intravenous antibiotics for 14 days demonstrated a reduc-
tion in sputum bacterial load and markers of airway inflammation after antibiotic treatment[56].  
 
Justification of the recommendations 
In the absence of any direct data comparing longer and shorter courses of antibiotics, we suggest con-
tinuing the usual practice of treating acute exacerbations of bronchiectasis with 14 days of antibiotics 
on the basis of the patient’s prior microbiology testing and the severity of the exacerbation. Patients 
have diverse views on the duration of antibiotics for exacerbations, with some preferring longer 
courses, and other patients wishing to use shorter courses if possible.    
 {PAGE  } 
 
Implementation considerations 
It is possible that shorter courses of antibiotics may be appropriate in some cases. The Task Force panel 
suggests that mild exacerbations, exacerbations in mild patients, those associated with pathogens more 
sensitive to antibiotics (e.g. S. pneumoniae), or patients with a rapid return to baseline state may benefit 
from shorter courses, however evidence supporting shorter course treatment is lacking Otherwise, in 
patients with lack of recovery by 14 days of antibiotic therapy we suggest re-evaluation of the patients 
clinical condition and a new microbiological investigation. Sending a sputum sample at the start of an 
exacerbation is helpful to guide choice of antibiotics in the event of inadequate response to initial ther-
apy. Due to variations in antibiotic use and healthcare practices across Europe, we do not address choice 
of specific antibiotics, or the role of combination vs. monotherapy in this guideline.  
Further research studies assessing the optimal duration of antibiotics are recommended.  
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Question 3: Is eradication treatment beneficial for treating ronchiectasis patients with a new 
isolate of a potentially pathogenic microorganism in comparison to no eradication treatment? 
 
Recommendations 
We suggest that adults with bronchiectasis with a new isolation of P. aeruginosa should be offered erad-
ication antibiotic treatment (conditional recommendation, very low quality of evidence). 
We suggest not offering eradication antibiotic treatment to adults with bronchiectasis following new 
isolation of pathogens other than P. aeruginosa (conditional recommendation, very low quality of evi-
dence)  
 
Summary of the evidence 
Eradication treatment refers to any antibiotic treatment given with the express intention of achieving 
complete clearance of the pathogen from the airway. In bronchiectasis, eradication treatment regimens 
vary, but there is some evidence suggesting that a regimen including a nebulized antibiotic achieves 
greater rates of clearance and clinical benefits than intravenous treatment alone[57]. 
 
Chronic airway infection in adult patients with bronchiectasis is frequent and usually associated with 
worse outcomes such as more exacerbations and poorer quality of life[15, 58]. Definitions of chronic 
airway infection in bronchiectasis are not established but a systematic review identified that the most 
frequent definition used in bronchiectasis studies is 2 or more isolates of the same organism at least 3 
months apart in one year[15]. Unfortunately, in patients with persistent infections, there is little evi-
dence about the beneficial effects of pathogen eradication beyond P. aeruginosa. 
We could not identify any randomised controlled trial (RCT) directly addressing the question. Therefore 
we included two studies that investigated whether eradication treatment in adult patients with bron-
chiectasis improved clinical outcomes compared to the patients own baseline[59, 60]. Pooled analysis 
provides some evidence of the potential benefits of P. aeruginosa eradication in terms of negative spu-
tum samples, frequency of subsequentexacerbations and quality of life but the evidence is indirect and 
considered of low quality. 
In particular, the retrospective observational study of White et al. analysed different eradication treat-
ment regimens: IV antibiotics (12 cases), IV antibiotics followed by inhaled antibiotics (13 cases), and 
oral ciprofloxacin alone. 25 patients across all groups received 3 months of inhaled colistin. Initial clear-
ance rate from sputum was 80%, but 54% of all patients remained P. aeruginosa free at follow-up and 
the exacerbation rate fell from 3.93 to 2.09 per year after the eradication treatment. In addition, two 
thirds of patients experienced clinical improvement although lung function remained unchanged.  
Orriols et al. performed a 15-month single-masked, RCT in 35 patients with early P.  aeruginosa infec-
tion[57]. These patients received initial therapy with IV ceftazidime or tobramycin followed by three 
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months of 300mg of nebulised tobramycin BD or placebo. At the end of follow-up (12 months), 54% of 
patients were free of P. aeruginosa in the tobramycin group vs. 29% in the placebo group. Despite some 
potential methodological limitations, this study showed that the median time to recurrence of P. aeru-
ginosa was longer in the treatment arm compared to placebo and numbers of exacerbations and hospi-
tal admissions were lower in the nebulised tobramycin group. The impact of eradication treatments on 
the development of antibiotic resistance was not extensively studied. This study had no control group 
and so is limited in terms of informing whether eradication is effective. 
There is no clear evidence to support one regimen over another, and therefore Figure 3 illustrates some 
commonly used regimes. 
  
 
Justification of the recommendation 
The poor clinical outcomes associated with chronic P. aeruginosa infection, the data from one observa-
tional study and the clinical experience in CF suggests that P. aeruginosa eradication may positively 
influence important clinical outcomes including exacerbation frequency.  
There is no evidence to support eradication of organisms other than P. aeruginosa and in organisms 
that are not so clearly associated with poorer outcomes, the risk-benefit ratio is less in favour of eradi-
cation treatment. 
 
Implementation considerations 
Identification of new isolates of P. aeruginosa requires regular sputum surveillance which has resource 
implications. We suggest as a minimum that patients should have a sputum sample sent when clinically 
stable once per year. In circumstances where the date of acquisition of P. aeruginosa is uncertain, a 
clinical judgement must be made on the likely success or otherwise of an eradication attempt. This 
guideline does not address attempted eradication of chronic P. aeruginosa infection, where the infection 
has been present for many years, as this is thought unlikely to be successful. The quality of evidence is 
low and further research is also needed on potential side effects of eradication therapies and, particu-
larly, the emergence of resistance or new infections.  
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Question 4: Should long-term anti-inflammatory agents be used in adult patients with bronchiec-
tasis?  
 
Recommendation: 
 We suggest not offering treatment with inhaled corticosteroids to adults with bronchiectasis 
(conditional recommendation, low quality of evidence).  
 We recommend not offering statins for the treatment of bronchiectasis (strong recommendation, 
low quality of evidence). 
 We suggest that the diagnosis of bronchiectasis should not affect the use of inhaled corticoster-
oids in patients with comorbid asthma or COPD (Best practice advice, indirect evidence). 
 
We considered only studies of anti-inflammatory drugs that were at least 3 months in duration. Alt-
hough macrolides may have anti-inflammatory activity their role in bronchiectasis is discussed within 
PICO question 5 of these guidelines (regarding antibiotics). We identified six systematic reviews[61-
66] and 3 studies that met our inclusion criteria [67-69]. 
Hernando et al. reported a double-blind RCT over 6 months with 77 patients allocated to inhaled 
budesonide 400mcg BD or placebo with a primary outcome of lung function[69]. Tsang et al. reported 
a trial of inhaled fluticasone vs. placebo over 12 months in 86 patients with co-primary endpoints of 
24hour sputum volume and annual exacerbation frequency[67].  Mandal et al. studied atorvastatin in 
30 patients over 6 months compared to a  matched group receiving placebo with a primary outcome 
improvement in cough related quality of life measured by the Leicester cough questionnaire[68]. Over-
all the three studies included only 193 patients. Two of the studies assessed the effects of anti-inflam-
matories on exacerbations with a wide confidence interval RR 0.99 (0.76-1.30)[67, 69]. Hence no clear 
benefit on reducing exacerbations was noted. 
 
The effect on quality of life, using the SGRQ, was only reported in 2 studies (123 patients) [68, 69], with 
an observed improvement of 0.91 points (below the minimal clinically significant difference of 4 points, 
CI: -4.51 to +6.33). All 3 studies reported FEV1 and FVC as lung function outcomes [67-69]. No signifi-
cant benefit was seen with any of the treatments studied for lung function.  
 
The study design and small number of patients make these studies not optimal for safety assessment. 
Across the 3 studies the pooled estimate of suffering any adverse event was RR 2.75 (95%CI 1.21-6.25) 
as compared to control. The adverse effect profile of both inhaled corticosteroids and statins has been 
well described.   
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The increase in pooled adverse events were largely driven by Mandal et al. who reported that adverse 
events led to withdrawal from the atorvastatin group (1 case of headache, 1 of diarrhoea, and 2 of com-
bined diarrhoea and headache)[68]. One was withdrawn due to liver function abnormalities at 3 
months. Ten (33%) patients receiving atorvastatin had an adverse event versus three (10%) allocated 
placebo (difference 23%, 95% CI 3–43; p=0.02). 
For the inhaled corticosteroid trials in bronchiectasis, adverse event reporting was incomplete. Known 
and frequent local adverse events across all diseases include dysphonia and oropharyngeal candidiasis. 
More severe adverse events include: alteration of the hypothalamic-pituitary-adrenal axis function, 
pneumonia, increased intraocular pressure, formation of cataracts and decreased bone density.  
 
Justification of recommendations  
There are no large trials of anti-inflammatory therapies in bronchiectasis and the existing studies show 
minimal and, in most cases, no clinically significant benefits. The increased frequency of adverse events, 
particularly with statins, justifies a recommendation against their use. The guideline panel concludes 
that inhaled corticosteroids do not have a role in the routine management of bronchiectasis. Inhaled 
corticosteroids have an established role in the treatment of asthma and a proportion of patients with 
COPD. In the absence of specific data in adult patients with bronchiectasis and these two conditions, the 
guideline panel concludes that the presence of bronchiectasis alone should not lead to a decision to 
withdraw inhaled corticosteroids from patients with established asthma or COPD.  
 
Implementation considerations  
We recommend randomized controlled trials of inhaled corticosteroids in bronchiectasis who are naïve 
to inhaled corticosteroid therapy. Inhaled corticosteroid use is, however, already widely used in bron-
chiectasis. In those already treated with inhaled corticosteroids and no clear history of asthma or COPD 
a randomized controlled trial of inhaled corticosteroid withdrawal may help define true utility of this 
widely prescribed therapy.  
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Question 5: Is long-term antibiotic treatment ( 3 months) compared to no treatment beneficial 
for treating adult bronchiectasis patients? 
 
Recommendations: 
 We suggest offering long-term antibiotic treatment for adults with bronchiectasis who have 
three or more exacerbations per year (conditional recommendation, moderate quality evidence). 
All subsequent recommendations refer to patients with three or more exacerbations per year. 
 
o We suggest long-term treatment with an inhaled antibiotic for adults with bronchiectasis 
and chronic P. aeruginosa infection (conditional recommendation, moderate quality evi-
dence). 
 
o We suggest long-term treatment with macrolides (azithromycin, erythromycin) for 
adults with bronchiectasis and chronic P. aeruginosa infection in whom an inhaled anti-
biotic is contraindicated, not tolerated or not feasible (conditional recommendation, low 
quality evidence). 
 
o We suggest long-term treatment with macrolides (azithromycin, erythromycin) in addi-
tion to or in place of an inhaled antibiotic, for adults with bronchiectasis and chronic P. 
aeruginosa infection who have a high exacerbation frequency despite taking an inhaled 
antibiotic (conditional recommendation, low quality evidence).  
 
o We suggest long-term treatment with macrolides (azithromycin, erythromycin) for 
adults with bronchiectasis not infected with P. aeruginosa (conditional recommendation, 
moderate quality evidence). 
 
o We suggest long-term treatment with an oral antibiotic (choice based on antibiotic sus-
ceptibility and patient tolerance) for adults with bronchiectasis not infected with P. aeru-
ginosa in whom macrolides are contraindicated, not tolerated or ineffective (conditional 
recommendation, low quality evidence). 
 
o We suggest long-term treatment with an inhaled antibiotic for adults with bronchiectasis 
not infected with P. aeruginosa in whom oral antibiotic prophylaxis is contraindicated, 
not tolerated or ineffective (conditional recommendation, low quality of evidence). 
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We identified 8 systematic reviews[70-77] and 17 relevant studies for this clinical question [37, 57, 
78-89][90, 91]. Our evidence summary suggests that long-term antibiotic use, pooling both inhaled 
and oral antibiotic data, reduces the number of exacerbations, time to first exacerbation, sputum pu-
rulence and breathlessness in adults with bronchiectasis; however, they are also associated to more 
adverse events and bacterial resistance.  
 
Three RCTs evaluating the effect of nebulised antibiotics in adults with bronchiectasis suggested bene-
ficial effects on exacerbation frequency and/or time to first exacerbation [70, 81, 83, 88]. In a study 
involving 144 adults with bronchiectasis and P. aeruginosa infection, colistin 1MU delivered twice daily 
through the I-neb was not associated with a statistically significant improvement in time to first exac-
erbation compared to placebo[88]. However, in a pre-planned analysis in adherent individuals (defined 
as taking 81% of doses recorded by the I-neb), the median (25th quartile) time to exacerbation was 
168 (65) days versus 103 (37) days in the colistin and placebo groups, respectively (p=0.038). A similar 
treatment effect was reported in a study evaluating nebulised liposomal ciprofloxacin in 42 adult pa-
tients with bronchiectasis and P. aeruginosa infection [83]. A 12-month single blind study of nebulised 
gentamicin in 65 adults with bronchiectasis predominantly infected with H. influenzae (n=26, 46%) or 
P. aeruginosa (n=24, 42%) showed significant benefits including fewer exacerbations compared to 0.9% 
saline-treated patients[81]. 
 
Three RCTs showed beneficial effects of macrolide antibiotics (azithromycin or erythromycin) on exac-
erbation frequency in adults with bronchiectasis: EMBRACE (141 patients on azithromycin or placebo 
for 6 months)[82], BAT (83 patients on azithromycin or placebo for 12 months)[85] and BLESS (117 
patients on erythromycin or placebo for 12 months)[84]. The EMBRACE study showed the rate of event-
based exacerbations was 0.59 per patient in the azithromycin group and 1.57 per patient in the placebo 
group in the 6-month treatment period (rate ratio 0.38, 95% CI 0.26–0.54; p<0.0001); the BAT study 
showed the median number of exacerbations in the azithromycin group was 0 (IQR 0-1), compared with 
2 (IQR 1-3) in the placebo group (p<0.001); and the BLESS study showed erythromycin significantly 
reduced protocol defined exacerbations compared to placebo (mean, 1.29 [95% CI, 0.93-1.65] vs. 1.97 
[95% CI, 1.45-2.48] per patient per year). Doses used in clinical trials or in clinical practice range from 
250mg azithromycin daily, 500mg or 250mg three times per week, and erythromycin 400mg twice 
daily.  
Historical RCTs evaluating penicillin and tetracycline based antibiotic regimens also suggest some ben-
efit in adults with bronchiectasis, with two long-term studies reporting less days off work and reduced 
sputum purulence with oxytetracycline [89] or amoxicillin treatment[78]. 
Important adverse events were reported with long-term antibiotic treatment. Diarrhoea was more 
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common with oral antibiotics than placebo in the macrolide studies, although treatment discontinua-
tion was rare[71-75]. There was also a 28% increase in the proportion of macrolide-resistant commen-
sal oropharyngeal Streptococci after 12 months treatment with erythromycin and a macrolide re-
sistance rate of 88% following 12 months of azithromycin [84, 85]. In contrast, there was no antimicro-
bial resistance reported after 6–12 months of nebulised colistin, dual release liposomal ciprofloxacin or 
gentamicin[81, 83, 88]. While these specific nebulised preparations were well tolerated, two phase III 
trials reported more frequent treatment-related adverse events (1.4 and 1.8 times greater) and discon-
tinuations (2.1 and 6.7 times greater) associated with nebulised aztreonam compared to placebo[37]. 
The most commonly reported adverse events were breathlessness, cough and increased sputum pro-
duction. The incidence of potential treatment-related adverse events such as QTc prolongation with 
macrolides, tinnitus/hearing loss with macrolides and inhaled aminoglycosides, and renal dysfunction 
with inhaled aminoglycosides is not known in people with bronchiectasis, but should be considered 
when weighing up the potential benefits and harms of long-term antibiotic treatment. 
Justification of recommendations (Fig. 4) 
The overall balance of desirable effects (particularly fewer exacerbations), undesirable effects (partic-
ularly gastrointestinal upset and antimicrobial resistance) and patient values favours long-term antibi-
otic treatment in selected patients. For individuals with P. aeruginosa, the currently available evidence 
supports continuous use of nebulised colistin[88]or gentamicin[81]). Nebulised aztreonam is not rec-
ommended due to the lack of efficacy with regard to quality of life improvement over 2 treatment cycles 
and a high adverse event rate reported in the pivotal phase III trials[37].Due to the relatively low num-
ber of participants with P. aeruginosa in the macrolide studies, the use of macrolide antibiotics is sug-
gested as a second-line option in patients with this organism[82, 84, 85]. However, for individuals with 
no evidence of P. aeruginosa infection, macrolide treatment is suggested as first-line treatment  due to 
the high-quality evidence for exacerbation reduction and acceptable side-effect profile[82, 84, 85]. 
 
Although the macrolide studies included a minimum exacerbation frequency of 1[82], 2[84] or 3[85] 
exacerbations in the year preceding enrolment as an entry criterion, the mean exacerbation frequency 
in the year prior to enrolment in each of the three studies was 3. Due to potential undesirable effects, 
the suggested threshold for starting long-term antibiotic treatment is ≥3 exacerbations per year. How-
ever, this threshold should reduce for individuals with: a history of severe exacerbation, relevant 
comorbidities such as primary/secondary immunodeficiency, patients in whom exacerbations are hav-
ing a significant impact on their quality of life or those with more severe bronchiectasis[9]. 
 
Before considering the prescription of long-term antibiotics, general aspects of bronchiectasis manage-
ment need to be optimised such as airway clearance and treating modifiable underlying causes. Careful 
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characterization of sputum pathogens (bacteria, mycobacteria and fungi) before and after implementa-
tion of long-term antibiotics is essential to direct antibiotic choices, monitor resistance patterns and 
identify treatment emergent organisms. Drug toxicity monitoring is also required, most notably with 
macrolides and inhaled aminoglycosides.  
 
Implementation considerations 
The use of inhaled antibiotics is associated with a 10-32% risk of bronchospasm[81, 92] and a super-
vised test dose with pre- and post- spirometry is recommended. Prior inhalation of a short-acting bron-
chodilator may prevent bronchospasm and, therefore, is advisable. 
Prior to long-term treatment with macrolides, we recommend excluding active NTM infection because 
macrolide monotherapy can increase the risk of macrolide resistance in NTM.  
No cost-effectiveness studies were identified regarding the use of long-term antibiotics in adult patients 
with bronchiectasis and further research will be required to determine if cyclical or continuous treat-
ment (possibly involving combinations of preparations) is optimal in terms of exacerbation frequency, 
treatment burden and risk of antimicrobial resistance. 
Figure 4 summarises the approach to long-term antibiotic treatment in adults with bronchiectasis sum-
marising the above guideline recommendations.  
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Question 6: Is long-term mucoactive treatment (≥ 3 months) compared to no treatment benefi-
cial for treating adult bronchiectasis patients?  
 
Recommendation 
We suggest offering long-term mucoactive treatment (≥ 3 months) in adult patients with bronchiectasis 
who have difficulty in expectorating sputum and poor quality of life and where standard airway clear-
ance techniques have failed to control symptoms (weak recommendation, low quality evidence).  
We recommend not to offer recombinant human DNase to adult patients with bronchiectasis (strong 
recommendation, moderate quality evidence)  
 
Summary of the evidence 
Airway clearance adjuncts such as mucolytics and hyperosmolar agents alter mucus viscosity and/or 
enhance mucociliary clearance. We identified 3 systematic reviews[93-95] and 5 relevant studies meet-
ing inclusion criteria for this clinical question[36, 96-99].Of these five RCTs, two were performed with 
dry powder mannitol at doses of 320mg (n= 343)[98] and 400mg twice daily (n= 461)[99], one with 
nebulised recombinant human DNase at a dose of 2.5mg twice daily (n= 349)[36], and two with nebu-
lised hypertonic saline (one with 4mL 7% once daily[96] or 5mL 6% twice daily[97], n=28 and n=40 
respectively). Only in two studies [98][36] was the treatment compared to placebo. In one study with 
mannitol[99] and in both studies with hypertonic saline[96, 97], the treatment was compared to low 
dose mannitol (50mg twice daily)[99] and isotonic saline [96], respectively. Three previous meta-anal-
yses of mucoactive and inhaled hyperosmolar agents in bronchiectasis prior to the most recent manni-
tol study[98] found insufficient evidence to draw firm conclusions on the effect of inhaled mucoactive 
and hyperosmolar treatment due to the significant differences in methodology, patient groups and find-
ings amongst the limited data available[93-95]. 
 
Patients with ≥2 exacerbations in the previous year and a baseline minimum SGRQ score of 30 who 
received mannitol showed a significantly greater improvement in total SGRQ score compared to con-
trols (low dose mannitol), although the difference between arms did not reach the minimal clinically 
important difference for the total SGRQ score[98]. An improvement in SGRQ components was shown in 
patients without chronic P. aeruginosa infection and with no long-term antibiotic treatment who re-
ceived hypertonic saline 7%[97]. 
None of the mucoactive agents significantly reduced the number of exacerbations, and the exacerbation 
rate was higher in the rhDNase group compared with placebo[36]. In patients with ≥2  exacerbations 
in the previous year, mannitol increased the time to first exacerbation[99].  In one study with hyper-
tonic saline 7% there were reductions in health care utilisation when comparing prospectively collected 
data between hypertonic saline and isotonic saline phases[97]. 
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In four studies, a tolerance test was performed at first administration: patients with mannitol-induced 
bronchospasm (16%) [98, 99] or a decrease in FEV1 of more than 10%[97] or 15%[96] after inhalation 
of hypertonic saline (7% and 6%, respectively) were excluded.  
In the 3-month study, 1.8% of patients randomised to mannitol experienced bronchospasm and 1.3% 
reported dyspnoea as opposed to none in the placebo group[98]. In the 13-month study, 20.2% of pa-
tients in the mannitol arm and 16.7% in the control group experienced adverse events related to study 
medication, most of which were judged to be mild or moderate[99]. Hypertonic saline was well toler-
ated with the number of patients with adverse events similar to those of the control groups.  
 
The mannitol studies both showed a significantly increased 24h sputum weight after treatment com-
pared to the control arms, consistent with improved mucociliary clearance [98, 99]. Mean 24h sputum 
weight decreased progressively during the study in both mannitol and control arms of both studies, but 
remained higher in the mannitol arms throughout.  
No change in lung function was observed in the studies with mannitol [98, 99]  or hypertonic saline 6% 
[96]. However, a significant improvement in FEV1% and FVC% was shown with hypertonic saline 7% 
at 3 months [97]. In contrast, a decrease in FEV1 was demonstrated in patients treated with RhDNase.  
 
There is insufficient evidence to permit evaluation of the use of oral mucolytics such as carbocisteine 
for bronchiectasis[94]. 
 
Justification of the recommendation  
In summary, despite the wide heterogeneity in studies (agent used, study design and treatment dura-
tion), overall the literature showed a small improvement in the time to first exacerbation with a slightly 
elevated but acceptable adverse event profile with inhaled long-term mucoactive agents. The reported 
improvements in quality of life indicate that a proportion of patients will experience a significant benefit 
with these agents, but many patients will not.  
The current research evidence and the ELF/EMBARC bronchiectasis patient advisory group suggest 
that patients give intermediate value to this treatment and acknowledge difficulties with its administra-
tion. Mucoactive agents are time-consuming and the therapeutic equipment, in the case of nebulizers, 
may be difficult to take outside of the patient’s home. 
 
Implementation considerations  
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The indication and type of treatment given should be tailored to each individual patient according to 
their baseline symptom profile (frequency and severity of exacerbations, quality of life, bronchial hy-
perreactivity, and sputum viscosity), baseline lung function and patient preferences. We suggest testing 
tolerance prior to starting therapy and to consider β-agonist premedication.  
Larger studies should be considered in the future to investigate optimal treatment, dosages, durations 
and combinations.  
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QUESTION 7: Is long-term bronchodilator treatment (>=3 months) compared to no treatment 
beneficial for adult bronchiectasis patients? 
 
Recommendations. 
We suggest not routinely offering long-acting bronchodilators for adult patients with bronchiectasis 
(conditional recommendation, very low quality of evidence)  
 
We suggest to offer long acting bronchodilators for patients with significant breathlessness on an indi-
vidual basis (weak recommendation, very low quality of evidence). 
 
We suggest using bronchodilators before physiotherapy, including inhaled mucoactive drugs, as well as 
before inhaled antibiotics, in order to increase tolerability and optimize pulmonary deposition in dis-
eased areas of the lungs (good practice point, indirect evidence).] 
 
We suggest that the diagnosis of bronchiectasis should not affect the use of long acting bronchodilators 
in patients with comorbid asthma or COPD [44, 45] (good practice point, indirect evidence).  
 
Where multiple inhaled therapies are used in the same patient, the sequence of treatments shown in 
figure 5 is commonly used by members of the task force.  
 
Summary of the evidence 
Very limited and indirect evidence is available for the benefit of the long-term treatment with broncho-
dilators from a systematic review that included a single trial, comparing high-dose inhaled corticoster-
oids to medium-dose inhaled corticosteroid/Long acting beta agonist combination[100]. The results 
from this study indicate some positive effects on symptom control / symptomatic improvement, in par-
ticular decreased dyspnoea, better cough control, better HRQL (measured by SGRQ symptoms domain), 
and reduced use of 2-agonist rescue medication. Specific side effects were generally mild (tremor, 
nervousness and tachycardia).  A systematic review identified major methodological and reporting con-
cerns relating to this trial[61]. However, extrapolating evidence from populations with other obstruc-
tive airway diseases some bronchiectasis subpopulations may benefit from bronchodilators, in partic-
ular subjects with chronic obstructive airflow limitation (FEV1/FVC <0.7; with or without FEV1 revers-
ibility to bronchodilators), or associated asthma in combination with inhaled corticosteroids[44, 45]. 
 
Justification of the recommendations 
We suggest the use of bronchodilators in patient with significant breathlessness due to the feasibility 
of application, the easy availability at a primary care level, the comparatively low treatment costs, and 
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a putatively positive ratio of benefits to adverse events. Appropriate inhalation device selection and 
inhaler technique training are recommended. If treatment with bronchodilators does not result in a 
reduction in symptoms it should be discontinued. There is no evidence to support the use of broncho-
dilators routinely as part of the management of bronchiectasis patients without symptomatic breath-
lessness.  According to both research evidence and patient advisory group feedback, it seems that pa-
tients regard this as a low risk and low burden intervention.  
 
Implementation considerations  
The intervention is easy to administer and acceptable to the majority of patients. Further investigator-
driven research on the benefit of bronchodilators in bronchiectasis in various clinical situations is 
needed. 
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QUESTION 8:  Are surgical interventions more beneficial compared to standard (non-surgical) 
treatment for adult BE patients? 
 
Recommendation. 
We suggest not offering surgical treatments for adult patients with bronchiectasis with the exception 
of patients with localised disease and a high exacerbation frequency despite optimisation of all other 
aspects of their bronchiectasis management (weak recommendation, very low quality of evidence).  
 
Summary of the evidence 
The rationale for surgical treatment of bronchiectasis is to break the vicious circle of bronchiectasis by 
removing the lung segments that are no longer functional, and preventing the contamination of adjacent 
lung zones.  The most frequent indication for the operation is recurrent infections with chronic symp-
toms such as productive cough, purulent sputum and haemoptysis[101, 102]. 
 
Lobectomy is the most frequently performed operation, but numerous options have been described 
(e.g. segmentectomy and pneumonectomy)[103-105]. Surgery is the procedure of choice for massive 
haemoptysis refractory to bronchial artery embolization, but emergency surgery in unstable patients is 
associated with higher morbidity and mortality reaching 37%[106]. Although bilateral bronchiectasis 
(reported in 5.8 to 30% of surgical series) are not an absolute contraindication for surgery[107], other 
options such as prolonged conservative treatment or bronchial arteries embolization are frequently 
used as an alternative. The video-assisted thoracoscopic surgery (VATS) is often preferred to better 
preserve lung function or reduce scarring. In comparison with open surgery, VATS has been reported 
to produce comparable symptomatic improvement (94 vs. 88%), but with shorter hospital stay, less 
complications (17.5 vs. 23.7%) and pain after VATS procedures[108]. Contraindications to VATS include 
major parenchymal or pleural fibrosis, and calcified nodes close to the hilar vessels. 
No RCTs of surgical treatment versus standard care were identified. A meta-analysis included 38 obser-
vational studies with 5541 patients, dealing with efficiency and safety of different surgical interventions 
to adult patients with bronchiectasis focused on three main outcomes: mortality, morbidity (adverse 
events) and quality of life improvement (symptomatic changes defined as reduction or alleviation of 
preoperative symptoms)[101]. 
The pooled mortality from 29 studies that focused on adult patients was 1.4% (95% CI, 0.8% - 
2.5%)[101]. Post-operative pooled morbidity for adults was analysed in 26 observational studies and 
was 16.2% (95% CI, 12.5% - 19.8%)[101]. It needs to be emphasized that there are no data comparing 
morbidity to continued medical non-surgical management alone. Moreover, according to the aforemen-
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tioned studies, some of the morbidity is considered relatively minor (air leak, atelectasis, wound infec-
tion). Symptomatic changes were analysed in 26 observational studies. In the pooled meta-analysis, 
complete alleviation of symptoms was seen in 71.5% (95% CI, 68 - 74.9) and reduction of preoperative 
symptoms was seen in 20.2% of the adult population (95% CI, 17.3 – 23.1)[101]. Other research has 
shown that extent of residual bronchiectasis and P. aeruginosa infection were reported as unfavourable 
prognostic factors[102]. 
 
Justification of the recommendations  
Overall, surgical interventions seem to be beneficial only in very carefully selected patients requiring 
the best risk-benefit profile of improved symptoms against the morbidity associated with surgery. 
Feedback from the ELF/EMBARC patient advisory group suggests that patients would choose surgery 
only if there was no effective medical option for treatment and this feedback informs the recommenda-
tion.  
 
Implementation considerations 
Involvement of an experienced surgeon in partnership with an expert respiratory physician is advisable 
if surgical treatment is being considered. Attention should be paid to pre-operative nutritional status 
and pulmonary rehabilitation. More research is needed on surgical interventions. Although a random-
ized trial would be very challenging future studies should include a matched control population with 
meticulous description of other treatments used in both populations.  
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Question 9: Is regular physiotherapy (airway clearance and/or pulmonary rehabilitation) more bene-
ficial than control (no physiotherapy treatment) in adult bronchiectasis patients? 
 
Recommendations.  
 We suggest that patients with chronic productive cough or difficulty to expectorate sputum 
should be taught an airways clearance technique (ACT) by a trained respiratory physiotherapist 
to perform once or twice daily (weak recommendation, low quality of evidence).  
 We recommend that adult patients with bronchiectasis and impaired exercise capacity should 
participate in a pulmonary rehabilitation program and take regular exercise. All interventions 
should be tailored to the patient’s symptoms, physical capability and disease characteristics 
(strong recommendation, high quality of evidence).  
Summary of the evidence (Figure 6) 
In bronchiectasis, it is common belief that physiotherapy can improve mucus clearance and reduce lung 
inflammation and risk of infection. In addition, it is well accepted by patients. Respiratory physiother-
apy includes ACTs and pulmonary rehabilitation (PR)[109, 110]. ACTs consist of breathing techniques 
e.g. active cycle of breathing and autogenic drainage, sometimes combined with an instrument e.g. flut-
ter or Acapella, that modify expiratory flow and volumes or produce chest wall oscillations in order to 
increase mucus clearance[111-115]. The principal effect obtained by ACTs is an increase in sputum 
volume[111, 115, 116] and a reduced impact of cough on quality of life[112-117]. Interesting, but still 
preliminary data, shows reduced peripheral airways obstruction, less inflammatory cells in sputum and 
improved exercise capacity after ACTs[112, 115, 117]. The aim of a PR programme is to improve exer-
cise tolerance and quality of life through  a tailored standardized exercise protocol[118-120]. 
We identified 3 systematic reviews[109, 121, 122] and several additional trials. We included a total of 
14 clinical trials in our analysis[96, 111, 113-115, 117-120, 123-127]. 
The pooled analysis shows that PR has a clear impact on exercise capacity immediately after the pro-
gram and some non-significant trend to improved quality of life (SGRQ)[119, 120, 122, 125, 126]. How-
ever, the unpooled study of Mandal et al. (PR duration [8 weeks] shorter than for pooled studies) de-
scribed that improvements on exercise capacity and patient’s quality of life may be maintained for a 
longer period of time[128]. Finally, there is one publication showing an impact of PR (8 weeks of super-
vised exercise training and review of ACTs) decreasing the frequency of exacerbations (median 1[IQR 
1-3]) vs. 2[1-3]; p = 0.012) over 12-month follow-up and longer time to first exacerbation (8 vs. 6 
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months; p = 0.047)[119]. The reported impact of both ACTs and PR on pulmonary function is not clini-
cally important[110-112, 115, 124] 
 
Justification of the recommendations  
The evidence for airways clearance techniques is weak because the studies are small and poorly com-
parable due to methodological issues. However, most studies demonstrated a significant increase of 
sputum volume. The evidence is stronger for PR showing improvements in exercise capacity, cough 
symptoms and quality of life, and possibly a reduction in exacerbations. The benefits of PR are achieved 
in 6 to 8 weeks and maintained for between 3 to 6 months. Finally, there are no relevant adverse effects 
and the bronchiectasis patients advisory group value the intervention. 
Implementation considerations  
The research priorities in physiotherapy are: larger controlled studies with clinical outcomes (exacer-
bations, cough and quality of life); larger controlled studies including physiotherapy training plus mu-
coactive agents such as hypertonic saline; the role of PR on exacerbations; and finally, the compliance 
with these interventions over a longer period of time (>12 months)[129]. 
 
SUMMARY 
Management of bronchiectasis aims to reduce exacerbations, reduce symptoms, improve quality of life 
[130][131] and reduce the risk of future complications such as lung function decline[132] and severe 
exacerbations[133]. Treatment decisions must balance the potential beneficial effects of the interven-
tion against the burden of treatment and the risk of adverse events. It is important to take into account 
the patients values and preferences in all treatment decisions, alongside the history of exacerbations, 
quality of life [130][131], severity of disease[9] and underlying aetiology [22], all of which can impact 
on the patients long-term outcome [134-136]. 
The purpose of clinical guidelines is to improve the quality of patient care and to promote safe, effective 
and cost-effective treatment. The majority of recommendations in this guideline are conditional and 
based on low quality evidence. One outcome of this guideline should be to promote further research 
into the optimal treatment of patients with bronchiectasis. Bronchiectasis is a rapidly evolving field and 
our recommendations will require to be revised as additional data becomes available in the coming 
years.  
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